COMP <GO>
SYRE vs JNJ // REVENUE GROWTH (YOY)
Spyre Therapeutics Inc. (NASDAQ) VS. Johnson & Johnson (NYSE) • 15-METRIC TALLY: SYRE 4
— JNJ 5
▲ REVENUE GROWTH (YOY) LEADER: SYRE
LAST: $95.51 (-1.09%) • MKT CAP: $9.97B
revenue-growth
17.60%
LAST: $270.56 (-0.97%) • MKT CAP: $651.32B
revenue-growth
6.00%
15-METRIC INSTITUTIONAL SIDE-BY-SIDE SCORECARD (SYRE VS. JNJ)
EMERALD CELL = QUANTITATIVE EDGE
| INSTITUTIONAL METRIC | SYRE | JNJ | SPREAD (A - B) | ADVANTAGE | DEDICATED URL |
|---|---|---|---|---|---|
| Gross Profit Margin | — | 67.90% | — | TIE | /gross-margins <GO> |
| Return on Invested Capital (ROIC) | -20.00% | 25.50% | -45.50 | JNJ | /roic <GO> |
| EV/EBITDA & P/E Valuation | — | 18.5x | — | TIE | /valuation <GO> |
| Free Cash Flow Yield | -1.64% | 2.97% | -4.61 | JNJ | /fcf-yield <GO> |
| Operating Margin | — | 34.70% | — | TIE | /operating-margins <GO> |
| Net Profit Margin | — | 28.50% | — | TIE | /net-margins <GO> |
| Revenue Growth (YoY) ACTIVE | 17.60% | 6.00% | +11.60 | SYRE | /revenue-growth <GO> |
| Dividend Yield & FCF Payout Safety | 0.00% | 0.00% | 0.00 | TIE | /dividend-safety <GO> |
| Altman Z-Score & Debt/Equity | 26.00 | 5.59 | +20.41 | SYRE | /balance-sheet <GO> |
| Piotroski F-Score Quality | 5/9 | 8/9 | -3.00 | JNJ | /piotroski-score <GO> |
| Options Implied Move & Put/Call Skew | — | — | — | TIE | /options-implied-move <GO> |
| RSI-14 & 200D SMA Momentum | 55.4 | 55.3 | +0.10 | SYRE | /rsi-technicals <GO> |
| 10Y Yield & FRED Macro Beta | 0.89 | 1.08 | -0.19 | JNJ | /macro-sensitivity <GO> |
| Forward P/E Multiple | 22.0x | 23.0x | -1.00 | SYRE | /forward-pe <GO> |
| Enterprise Scale & Market Cap | $9.97B | $651.32B | -$641.35B | JNJ | /market-cap <GO> |
5-YEAR HISTORICAL XBRL REVENUE & MARGIN TRAJECTORY SEC FORM 10-K FY
| FISCAL YEAR | SYRE REV | JNJ REV | SYRE GROSS % | JNJ GROSS % | SYRE FCF | JNJ FCF |
|---|---|---|---|---|---|---|
| FY 2025 | $586.8M | $94.19B | — | 67.9% | -$169.3M | $19.70B |
| FY 2024 | $584.0M | $88.82B | — | 69.1% | -$157.4M | $19.84B |
| FY 2023 | $886.0K | $85.16B | — | — | -$99.9M | $18.96B |
FRED MACRO REGIME CORRELATION COMPARISON PEARSON r
SYRE // BETA 0.89
JNJ // BETA 1.08